Boehringer Ingelheim has funded the publication of a new educational resource detailing HER2 activating mutations. Designed for US Healthcare Professionals, the material explains how mutations across receptor domains dysregulate signaling.
The analysis covers three key domains and their distinct roles in function. Crucially, it highlights consequences when mutations induce constitutive, ligand-independent activation driving oncogenesis.